摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,6-二甲基-1H-吡啶-2-酮 | 27992-31-0

中文名称
5,6-二甲基-1H-吡啶-2-酮
中文别名
——
英文名称
5,6-dimethyl-2(1H)-pyridone
英文别名
5,6-dimethyl-2-pyridone;5,6-dimethyl-1H-pyridin-2-one;5,6-dimethylpyridin-2(1H)-one;2-Oxo-5,6-dimethyl-1,2-dihydro-pyridin;5,6-Dimethyl-pyridon-2;5,6-dimethyl-2-pyridon;5,6-dimethyl-1H-pyridin-2-one
5,6-二甲基-1H-吡啶-2-酮化学式
CAS
27992-31-0
化学式
C7H9NO
mdl
MFCD09881364
分子量
123.155
InChiKey
MIMWDGDLJCJLQS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.285
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933399090

SDS

SDS:c511b32e24dbc5bb58d0a8af040c2616
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5,6-二甲基-1H-吡啶-2-酮 manganese(IV) oxide正丁基锂四甲基乙二胺硫酸苄基三乙基氯化铵氢气硝酸三乙胺三氯氧磷 作用下, 以 四氢呋喃甲醇二氯甲烷甲苯乙腈 为溶剂, 80.0 ℃ 、202.65 kPa 条件下, 反应 25.0h, 生成 N-[2-methoxy-5,6-dimethyl-4-(3-methylbenzoyl)pyridin-3-yl]-2,2-dimethylpropionamide
    参考文献:
    名称:
    4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones:  In Vitro Evaluation of New C-3-Amino-Substituted and C-5,6-Alkyl-Substituted Analogues against Clinically Important HIV Mutant Strains
    摘要:
    In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L1001 + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A] which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50'S) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.
    DOI:
    10.1021/jm0408621
  • 作为产物:
    描述:
    4-甲基-5-氧己腈aluminum oxide磺酰氯 作用下, 反应 4.0h, 生成 5,6-二甲基-1H-吡啶-2-酮
    参考文献:
    名称:
    Gisby, Graham P.; Royall, Sven E.; Sammes, Peter G., Journal of the Chemical Society. Perkin transactions I, 1982, p. 169 - 174
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DEO-GLCNAC TRANSFÉRASE (OGT) ET UTILISATIONS DE CEUX-CI
    申请人:HARVARD COLLEGE
    公开号:WO2016004180A1
    公开(公告)日:2016-01-07
    The present invention provides inhibitors of O-GlcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, metabolic diseases, neurodegenerative diseases, proliferative diseases (e.g., cancers), autoimmune diseases, and inflammatory diseases.
    本发明提供了O-葡萄糖基-N-乙酰氨基葡萄糖转移酶的抑制剂。通常,这些抑制剂是喹诺酮-6-磺酰胺。本发明还提供了由此产生的药物组合物及其在糖尿病及其并发症、代谢性疾病、神经退行性疾病、增殖性疾病(例如,癌症)、自身免疫性疾病和炎症性疾病中的使用方法。
  • [EN] PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION EN TANT QUE MEDICAMENTS POUR LE TRAITEMENT DES MALADIES LIEES AUX RECEPTEURS MCH
    申请人:TAISHO PHARMA CO LTD
    公开号:WO2006035967A1
    公开(公告)日:2006-04-06
    The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
    本发明涵盖了化学式(I)的新型取代吡啶化合物,其作为MCH受体拮抗剂。这些组合物及其药物组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴饮暴食障碍包括暴食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾症方面具有用处。
  • NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS
    申请人:Mutabilis
    公开号:EP3357924A1
    公开(公告)日:2018-08-08
    The present invention relates to compound of formula (I) and their use for treating bacterial infections
    本发明涉及化合物(I)的结构以及它们在治疗细菌感染中的应用。
  • [EN] BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2013078254A1
    公开(公告)日:2013-05-30
    The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula 1: wherein Het, X, R1 and R2 are as defined herein.
    本发明提供了化合物,包括已分离的对映体、已分离的异构体、溶剂合物和其药学上可接受的盐,其化学式如下:其中Het、X、R1和R2的定义如本文所述。
  • Reactions of 1-unsubstituted tautomeric 2-pyridones with benzyne.
    作者:MASAYUKI KUZUYA、AKIHIRO NOGUCHI、SHOJI KAMIYA、TAKACHIYO OKUDA
    DOI:10.1248/cpb.33.2313
    日期:——
    The reactions of 1-unsubstituted 2-pyridones with benzyne afforded the Diels-Alder adduct, 5, 6-benzo-2-azabarrelen-3 (2H)-ones, together with a large amount of the Michael-type adduct, 2-phenoxypyridines.
    1-未取代的2-吡啶酮与苯炔的反应生成了Diels-Alder加成产物5, 6-苯并-2-氮杂巴雷ланы-3 (2H)-酮,同时生成了大量的迈克尔型加成产物2-苯氧基吡啶。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-